Research presented at
#OW2024 shines a light on a blind spot in
#DrugLabeling for persons with
#obesity. A big thx to MedCentral, Caroline Apovian, and Fatima Cody Stanford for shining light on this. Looking for FDA and Merck to do the right thing.
https://conscienhealth.org/2024/11/ow2024-a-blind-spot-in-drug-labeling-for-persons-with-obesity/
OW2024: A Blind Spot in Drug Labeling for Persons with Obesity - ConscienHealth
Research presented at ObesityWeek 2024 shines a light on a blind spot in drug labeling for persons with obesity.
Kudos to U.S. Representative Robin Kelly for pressing #FDA to protect people living with #obesity in #DrugLabeling and clinical trials.
Scientists know this is a problem. FDA can fix it. They should.
https://conscienhealth.org/2024/05/fda-faces-questions-about-drug-risks-for-people-with-obesity/
FDA Faces Questions About Drug Safety for People with Obesity - ConscienHealth
FDA faced questions in Congress this week about drug safety for people with obesity, arising from their exclusion in clinical trials.
All with one voice, every major
#obesity group in the U.S. called on FDA and PhRMA yesterday to fix an appalling blind spot in
#ClinicalTrials &
#DrugLabeling.
Thx to OAC, STOP Obesity Alliance, Obesity Medicine Association, & ASMBS
https://conscienhealth.org/2023/11/fix-the-blind-spot-in-drug-trials-says-every-major-obesity-group/
Fix the Blind Spot in Drug Trials Says Every Major Obesity Group - ConscienHealth
An appalling blind spot in drug trials and labeling exists for people with obesity. Tuesday, every major obesity group called for a fix.
A Troubling Gap: Body Size Diversity in Clinical Trials - ConscienHealth
From the perspective of medical ethics, excluding size diversity from clinical trials and labeling for new drugs raises serious issues.
ConscienHealth